Delayed
Nasdaq Stockholm
09:39:23 03/05/2024 BST
|
5-day change
|
1st Jan Change
|
201
SEK
|
0.00%
|
|
+9.24%
|
+33.11%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
444.1
|
754.5
|
561.5
|
757
|
1,806
|
-
|
-
|
Enterprise Value (EV)
1 |
444.1
|
754.5
|
527.8
|
757
|
1,766
|
1,806
|
1,806
|
P/E ratio
|
-
|
46.9
x
|
-
|
-
|
-
|
-
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.11
x
|
-
|
2.28
x
|
2.57
x
|
3.2
x
|
2.83
x
|
2.54
x
|
EV / Revenue
|
3.11
x
|
-
|
2.14
x
|
2.57
x
|
3.13
x
|
2.83
x
|
2.54
x
|
EV / EBITDA
|
-
|
-
|
12.5
x
|
12.1
x
|
14.3
x
|
10.9
x
|
9.6
x
|
EV / FCF
|
-
|
-
|
22,088,270
x
|
31,059,165
x
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
0%
|
0%
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
4,828
|
5,013
|
5,013
|
5,013
|
8,985
|
-
|
-
|
Reference price
2 |
92.00
|
150.5
|
112.0
|
151.0
|
201.0
|
201.0
|
201.0
|
Announcement Date
|
18/02/21
|
17/02/22
|
17/02/23
|
16/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
142.6
|
-
|
246.4
|
294.9
|
564.2
|
637.6
|
710.2
|
EBITDA
1 |
-
|
-
|
42.1
|
62.6
|
123.3
|
165.8
|
188.2
|
EBIT
1 |
-
|
-
|
32.41
|
48.3
|
95.4
|
133.9
|
152.7
|
Operating Margin
|
-
|
-
|
13.15%
|
16.38%
|
16.91%
|
21%
|
21.5%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
8.273
|
16.1
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
5.8%
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
3.210
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
23.9
|
24.37
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
9.7%
|
8.27%
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
56.76%
|
38.94%
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
18/02/21
|
17/02/22
|
17/02/23
|
16/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
61.6
|
63.3
|
-
|
61.84
|
-
|
75.09
|
70.11
|
77.3
|
139.7
|
141.6
|
134.3
|
148.6
|
EBITDA
1 |
9.8
|
11.2
|
-
|
-
|
-
|
15.7
|
15.5
|
17.7
|
17
|
31.9
|
33.6
|
40.9
|
EBIT
1 |
7.5
|
8.9
|
-
|
-
|
-
|
11.95
|
11.92
|
14
|
10.3
|
24.8
|
26.9
|
33.4
|
Operating Margin
|
12.18%
|
14.06%
|
-
|
-
|
-
|
15.91%
|
17.01%
|
18.11%
|
7.37%
|
17.51%
|
20.03%
|
22.48%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
6.514
|
-
|
3.417
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
1.300
|
-
|
0.6800
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/04/22
|
15/07/22
|
27/10/22
|
17/02/23
|
27/04/23
|
14/07/23
|
26/10/23
|
16/02/24
|
25/04/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
33.7
|
-
|
40
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
23.9
|
24.4
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
16.2%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
2.13
|
1.41
|
5
|
6
|
-
|
Capex / Sales
|
-
|
-
|
0.86%
|
0.48%
|
0.89%
|
0.94%
|
-
|
Announcement Date
|
18/02/21
|
17/02/22
|
17/02/23
|
16/02/24
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| +33.11% | 166M | | +9.90% | 27.12B | | -30.75% | 3.07B | | -15.97% | 2.52B | | +18.11% | 2.47B | | +3.70% | 2B | | -9.47% | 1.91B | | -2.22% | 1.47B | | +2.24% | 1.33B | | +18.92% | 1.19B |
Medical Supplies
|